Search Results - "Dumbrava, Ecaterina Ileana"

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer by Meric-Bernstam, Funda, Johnson, Amber M, Dumbrava, Ecaterina E Ileana, Raghav, Kanwal, Balaji, Kavitha, Bhatt, Michelle, Murthy, Rashmi K, Rodon, Jordi, Piha-Paul, Sarina A

“…The introduction of HER2-targeted therapy for breast and gastric patients with ( ) amplification/overexpression has led to dramatic improvements in oncologic…”
Get full text

Precision Oncology Decision Support: Current Approaches and Strategies for the Future by Kurnit, Katherine C, Dumbrava, Ecaterina E Ileana, Litzenburger, Beate, Khotskaya, Yekaterina B, Johnson, Amber M, Yap, Timothy A, Rodon, Jordi, Zeng, Jia, Shufean, Md Abu, Bailey, Ann M, Sánchez, Nora S, Holla, Vijaykumar, Mendelsohn, John, Shaw, Kenna Mills, Bernstam, Elmer V, Mills, Gordon B, Meric-Bernstam, Funda

“…With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular…”
Get full text

Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing by Nowlen, Carol J, Daniels, Molly, Uzunparmak, Burak, Ileana Dumbrava, Ecaterina E, Yuan, Ying, Patel, Keyur P, Rayes, Nadine, Harkenrider, Jacqueline, Wathoo, Chetna, Veazie, Jennifer, Luna, Krystle A, Wang, Wanlin, Horombe, Chacha, Javle, Milind, Ahnert, Jordi Rodon, Yap, Timothy A, Arun, Banu, Lu, Karen H, Meric-Bernstam, Funda

“…Genomic profiling is performed in patients with advanced or metastatic cancer, in order to direct cancer treatment, often sequencing tumor-only, without a…”
Get full text

Phase 2 study of pembrolizumab in patients with advanced rare cancers by Naing, Aung, Meric-Bernstam, Funda, Stephen, Bettzy, Karp, Daniel D, Hajjar, Joud, Rodon Ahnert, Jordi, Piha-Paul, Sarina A, Colen, Rivka R, Jimenez, Camilo, Raghav, Kanwal P, Ferrarotto, Renata, Tu, Shi-Ming, Campbell, Matthew, Wang, Linghua, Sabir, Sarjeel H, Tapia, Coya, Bernatchez, Chantale, Frumovitz, Michael, Tannir, Nizar, Ravi, Vinod, Khan, Saria, Painter, Jeane M, Abonofal, Abulrahman, Gong, Jing, Alshawa, Anas, McQuinn, Lacey M, Xu, Mingxuan, Ahmed, Sara, Subbiah, Vivek, Hong, David S, Pant, Shubham, Yap, Timothy A, Tsimberidou, Apostolia M, Dumbrava, Ecaterina E Ileana, Janku, Filip, Fu, Siqing, Simon, Richard M, Hess, Kenneth R, Varadhachary, Gauri R, Amir Habra, Mouhammed

“…Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to…”
Get full text

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences by Yao, Shuyang, Meric-Bernstam, Funda, Hong, David, Janku, Filip, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Karp, Daniel, Subbiah, Vivek, Yap, Timothy Anthony, Ahnert, Jordi Rodon, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Wathoo, Chetna, Campbell, Erick, Yu, Lihou, Yamamura, Yuko, Fu, Siqing

“…Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying…”
Get full text

Challenges with biomarkers in cancer drug discovery and development by Ileana Dumbrava, Ecaterina, Meric-Bernstam, Funda, Yap, Timothy A

Get more information

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models by Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent, Akcakanat, Argun, Tapia, Coya, Yang, Fei, Bose, Priya Subash Chandra, Zheng, Xiaofeng, Dumbrava, Ecaterina Ileana, Aivado, Manuel, Meric-Bernstam, Funda

“…MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination…”
Get full text

Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy by Ileana Dumbrava, Ecaterina, Smith, Veronica, Alfattal, Rasha, El-Naggar, Adel K, Penas-Prado, Marta, Tsimberidou, Apostolia M

“…Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1…”
Get full text

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations by Pairawan, Seyed, Akcakanat, Argun, Kopetz, Scott, Tapia, Coya, Zheng, Xiaofeng, Chen, Huiqin, Ha, Min Jin, Rizvi, Yasmeen, Holla, Vijaykumar, Wang, Jing, Evans, Kurt W., Zhao, Ming, Busaidy, Naifa, Fang, Bingliang, Roth, Jack A., Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda

“…Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination…”
Get full text

Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors by Marcelo-Lewis, Kathrina L, Moorthy, Shhyam, Ileana-Dumbrava, Ecaterina

“…A major breakthrough in cancer treatment was ushered in by the development of immune checkpoint blockade therapy such as anti-CTLA4 antibody and anti-PD-1 and…”
Get full text

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial by Subbiah, Vivek, Dumbrava, Ecaterina Ileana, Jiang, Yunfang, Thein, Kyaw Z, Naing, Aung, Hong, David S, Fu, Siqing, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Janku, Filip, Meric-Bernstam, Funda, Kurzrock, Razelle, Falchook, Gerald

“…Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis…”
Get full text

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors by Sharma, Manish, Dumbrava, Ecaterina Ileana, Carvajal, Richard, Catenacci, Daniel, Emens, Leisha, Hanna, Glenn, Juric, Dejan, Kang, Yoon-Koo, Lee, Jeeyun, Lee, Keun-Wook, Li, Bob, Moore, Kathleen, Pegram, Mark, Pohlmann, Paula, Rasco, Drew, Spira, Alexander, Tan, Antoinette, Wang, Ding, Ackerman, Shelley, LeBlanc, Heidi, Dornan, David, Kowanetz, Marcin, Alonso, Michael, Perez, Edith

“…BackgroundIn spite of advances made in the management of patients with HER2-expressing or -driven solid tumors, there remains a significant unmet need for…”
Get full text

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies by Subbiah, Vivek, Coleman, Niamh, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Janku, Filip, Rodon, Jordi, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Fu, Siqing, Hong, David S, Zhang, Shizhen, Sun, Ming, Jiang, Yunfang, Roszik, Jason, Song, Juhee, Yuan, Ying, Meric-Bernstam, Funda, Naing, Aung

“…Sapanisertib (CB-228/TAK-228) is a potent, selective ATP-competitive, dual inhibitor of mTORC1/2. Metformin is thought to inhibit the mTOR pathway through…”
Get full text

Autoimmune hypophysitis by Ileana-Dumbrava, Ecaterina, Subbiah, Vivek

“…A 82-year-old male patient with metastatic lung adenocarcinoma presented to the outpatient clinic at the University of Texas MD Anderson Cancer Center…”
Get full text

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer by Tang, Chad, Hartley, Genevieve P, Couillault, Coline, Yuan, Ying, Lin, Heather, Nicholas, Courtney, Srinivasamani, Anupallavi, Dai, James, Dumbrava, Ecaterina E Ileana, Fu, Siqing, Karp, Daniel D, Naing, Aung, Piha-Paul, Sarina A, Rodon Ahnert, Jordi, Pant, Shubham, Subbiah, Vivek, Yap, Timonthy A, Tsimberidou, Apostolia M, Guerrero, Paola, Dhebat, Sarah, Proia, Theresa, Curran, Michael A, Hong, David S

“…ObjectiveTo evaluate signal transducer and activator of transcription 3 (STAT3) inhibition we conducted a co-clinical trial testing danvatirsen, a STAT3…”
Get full text

Personalized cancer therapy-leveraging a knowledge base for clinical decision-making by Dumbrava, Ecaterina Ileana, Meric-Bernstam, Funda

“…Next-generation sequencing (NGS), also known as massively parallel sequencing, is rapidly being incorporated into oncology practice. Interpretation of genomic…”
Get full text

Hypopigmented Skin Lesions After Immunotherapy by Dumbrava, Ecaterina Ileana, Ivan, Doina, Subbiah, Vivek

Get more information

Abstract B07: TAK228 enhances antitumor activity of eribulin in triple-negative breast cancer by Owusu-Brackett, Nicci, Evans, Kurt W., Akcakanat, Argun, Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda

“…Abstract Background: Phosphatase and tensin homologue deleted from chromosome 10 (PTEN) negatively regulates the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR…”
Get full text

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies by Hegde, Aparna, Jayaprakash, Priyamvada, Couillault, Coline A, Piha-Paul, Sarina, Karp, Daniel, Rodon, Jordi, Pant, Shubham, Fu, Siqing, Dumbrava, Ecaterina E, Yap, Timothy A, Subbiah, Vivek, Bhosale, Priya, Coarfa, Cristian, Higgins, Jack P, Williams, Eric T, Wilson, Thomas F, Lim, JoAnn, Meric-Bernstam, Funda, Sumner, Elizabeth, Zain, Hira, Nguyen, Di, Nguyen, Ly M, Rajapakshe, Kimal, Curran, Michael A, Hong, David S

“…As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates…”
Get full text

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss by Owusu-Brackett, Nicci, Zhao, Ming, Akcakanat, Argun, Evans, Kurt W, Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda

“…PTEN-deficient tumors are dependent on PI3Kβ activity, making PI3Kβ a compelling target. We evaluated the efficacy of PI3Kβ inhibitor AZD8186 on tumors with…”
Get full text